Literature DB >> 18381930

Endoglin (CD105): a marker of tumor vasculature and potential target for therapy.

Nikolaos A Dallas1, Shaija Samuel, Ling Xia, Fan Fan, Michael J Gray, Sherry J Lim, Lee M Ellis.   

Abstract

Endoglin (CD105) is an accessory protein of the transforming growth factor-beta receptor system expressed on vascular endothelial cells. Mutation of the endoglin gene is associated with hereditary hemorrhagic telangiectasias, or Osler-Weber-Rendu syndrome, and has been studied extensively in the context of this disease. The expression of endoglin is elevated on the endothelial cells of healing wounds, developing embryos, inflammatory tissues, and solid tumors. Endoglin is a marker of activated endothelium, and its vascular expression is limited to proliferating cells. Recent studies identified endoglin expression in several solid tumor types, with the level of expression correlating with various clinicopathologic factors including decreased survival and presence of metastases. Attempts to target endoglin and the cells that express this protein in tumor-bearing mice have yielded promising results.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18381930     DOI: 10.1158/1078-0432.CCR-07-4478

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  157 in total

1.  Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.

Authors:  Adam D Steg; Kerri S Bevis; Ashwini A Katre; Angela Ziebarth; Zachary C Dobbin; Ronald D Alvarez; Kui Zhang; Michael Conner; Charles N Landen
Journal:  Clin Cancer Res       Date:  2011-12-05       Impact factor: 12.531

2.  Discovery and characterization of novel microRNAs during endothelial differentiation of human embryonic stem cells.

Authors:  Jung Ki Yoo; Jumi Kim; Seong-Jun Choi; Hye Min Noh; Young Do Kwon; Hanna Yoo; Hyo Seon Yi; Hyung Min Chung; Jin Kyeoung Kim
Journal:  Stem Cells Dev       Date:  2012-02-07       Impact factor: 3.272

Review 3.  Endoglin-targeted cancer therapy.

Authors:  Ben K Seon; Akinao Haba; Fumihiko Matsuno; Norihiko Takahashi; Masanori Tsujie; Xinwei She; Naoko Harada; Shima Uneda; Tomoko Tsujie; Hirofumi Toi; Hilda Tsai; Yuro Haruta
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

4.  Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.

Authors:  Ines A Silva; Shoumei Bai; Karen McLean; Kun Yang; Kent Griffith; Dafydd Thomas; Christophe Ginestier; Carolyn Johnston; Angela Kueck; R Kevin Reynolds; Max S Wicha; Ronald J Buckanovich
Journal:  Cancer Res       Date:  2011-04-15       Impact factor: 12.701

5.  In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis.

Authors:  Yunan Yang; Yin Zhang; Hao Hong; Glenn Liu; Bryan R Leigh; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-04       Impact factor: 9.236

6.  ImmunoPET of CD146 in a Murine Hindlimb Ischemia Model.

Authors:  Carolina A Ferreira; Reinier Hernandez; Yunan Yang; Hector F Valdovinos; Jonathan W Engle; Weibo Cai
Journal:  Mol Pharm       Date:  2018-06-25       Impact factor: 4.939

7.  Control of RNA processing by a large non-coding RNA over-expressed in carcinomas.

Authors:  Rui Lin; Manami Roychowdhury-Saha; Chris Black; Andrew T Watt; Eric G Marcusson; Susan M Freier; Thomas S Edgington
Journal:  FEBS Lett       Date:  2011-01-23       Impact factor: 4.124

8.  Evaluation of a Novel Plasmid for Simultaneous Gene Electrotransfer-Mediated Silencing of CD105 and CD146 in Combination with Irradiation.

Authors:  Monika Savarin; Urska Kamensek; Katarina Znidar; Vesna Todorovic; Gregor Sersa; Maja Cemazar
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

Review 9.  Eradicating Cancer Stem Cells: Concepts, Issues, and Challenges.

Authors:  Gurpreet Kaur; Praveen Sharma; Nilambra Dogra; Sandeep Singh
Journal:  Curr Treat Options Oncol       Date:  2018-03-20

10.  Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.

Authors:  Benedetto Farsaci; Renee N Donahue; Michael A Coplin; Italia Grenga; Lauren M Lepone; Alfredo A Molinolo; James W Hodge
Journal:  Cancer Immunol Res       Date:  2014-08-04       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.